|Articles|October 1, 2009

Regulatory Roundup: FDA Revises Announcement of Tobacco Committee Selection Process, More...

Also, FDA bans candy and fruit-flavored cigarettes, EMEA moves to improve information management.

The US Food and Drug Administration announced an amendment to its Aug. 26, 2009, Federal Register posting regarding the selection process and nominations for a nonvoting industry representative on the tobacco products scientific advisory committee. The revised date for sending a letter to the agency about participating in the selection process is Oct. 26, 2009. The address for sending a letter was also changed to: Teresa L. Hays, FDA, Center for Tobacco Products, 9200 Corporate Blvd, Rockville, MD 20850-3229, 301.796.3699, Teresa.Hays@fda.hhs.gov. Finally, the text in the original announcement regarding the selection process was modified.

In related tobacco-industry news, FDA is making candy and fruit-flavored cigarettes, including cloves, illegal in the United States. The ban is authorized by the new Family Smoking Prevention and Tobacco Control Act and is part of a national effort by FDA to reduce smoking in America, according to an agency release.

The European Medicines Agency (EMEA) intends to fully implement its Product Information Management (PIM) approach, an initiative designed to improve information management, into its centralized procedure within two years, according to a statement of intent from the agency. PIM implementation is currently in a pilot phase where PIM submissions are only accepted subject to prior discussion with the EMEA. The agency's statement, however, has outlined four main milestones that will lead to full implementation of PIM. Those milestones are available on the EMEA website.
 


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.